×

Do you want to link to this External Site and leave Amgen.com.sg?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen website and leave Amgen.com.sg?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Singapore takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Singapore

About Amgen Singapore

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

On 20 November 2014, Amgen inaugurated its new biomanufacturing facility in Tuas Biomedical Park, marking the company's first manufacturing site in Asia. Built with the state-of-the-art modular, reconfigurable design that can be replicated in future facilities, this biologics facility was Amgen's first commercial-ready site aimed at increasing production capabilities and to allow greater medicine accessibility to patients around the world. Using a number of innovative technologies, this facility produces denosumab which is formulated into the medicines Prolia® and XGEVA® to treat osteoporosis and bone-related disorders in cancer patients.

A second facility at the same site is currently under construction and is intended for large chemical synthesis manufacturing. This new facility will be Amgen's first commercial API facility and will produce carfilzomib, the active pharmaceutical ingredient for Kyprolis® that treats multiple myeloma.

Most recently, Amgen opened a Singapore affiliate in December 2015 to market its innovative medicines for patients suffering from serious illnesses across the region.

Amgen's expansion in Singapore is expected to bring new jobs and innovative therapies. Amgen looks forward to being an active member in the local healthcare industry and partnering with the Government and industry organizations to encourage mutual growth and create a positive environment that further meets the needs of patients. This further strengthens Amgen's capabilities to address the region's growing healthcare needs and provide treatments for millions of patients across the Asia-Pacific region.